Spearhead Capital Advisors, LLC Acadia Pharmaceuticals Inc Transaction History

Spearhead Capital Advisors, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 28, 2022	SELL	$20.94 - $27.5 $270,733 - $355,547	-12,929 Closed	0 $0
Q4 2021 Jan 25, 2022	BUY	$16.79 - $27.09 $5,037 - $8,127	300 Added 2.38%	12,929 $302,000
Q3 2021 Oct 27, 2021	SELL	$15.78 - $24.77 $1,925 - $3,021	-122 Reduced 0.96%	12,629 $210,000
Q2 2021 Aug 10, 2021	BUY	$19.4 - $27.42 $247,369 - $349,632	12,751 New	12,751 $311,000
Q1 2021 Apr 28, 2021	SELL	$25.02 - $54.99 $138,785 - $305,029	-5,547 Closed	0 $0
Q4 2020 Feb 02, 2021	BUY	$41.04 - $56.79 $6,730 - $9,313	164 Added 3.05%	5,547 $297,000
Q3 2020 Oct 16, 2020	BUY	$36.42 - $57.0 $13,256 - $20,748	364 Added 7.25%	5,383 $222,000
Q2 2020 Jul 16, 2020	BUY	$39.26 - $52.73 $197,045 - $264,651	5,019 New	5,019 $243,000

280

156M

901K

314K

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.65B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

Get notified when there are updates to the investment portfolio of Spearhead Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Spearhead Capital Advisors, LLC with notifications on news.